pumabiotechnology.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
Meta Tags
| Title | Puma |
| Description | Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the acquisition, development and commercialization of novel therapeutics for the treatment of cancer. Puma in-licenses the global development and commercialization rights to PB272 |
| Keywords | Puma Biotechnology, biotechnology, nerlynx, neratinib, neratinib tablets, breast cancer, early stage, metastatic, drug development, pb272, clinical trials, oncology, her2+, biopharmaceutical, in-licensing, cancer treatment, oncology |
Server Information
| WebSite | |
| Host IP | 208.109.164.43 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
pumabiotechnology.com Valuation
|
US$26,173,698
Last updated: 2023-04-28 16:12:52
pumabiotechnology.com has Semrush global rank of 404,387. pumabiotechnology.com has an estimated worth of US$ 26,173,698, based on its estimated Ads revenue. pumabiotechnology.com receives approximately 3,020,043 unique visitors each day. Its web server is located in United States, with IP address 208.109.164.43. According to SiteAdvisor, pumabiotechnology.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$26,173,698 |
| Daily Ads Revenue | US$24,161 |
| Monthly Ads Revenue | US$724,811 |
| Yearly Ads Revenue | US$8,697,722 |
| Daily Unique Visitors | 201,337 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| pumabiotechnology.com. | A | 7199 | IP: 208.109.164.43 |
| pumabiotechnology.com. | NS | 3600 | NS Record: ns67.domaincontrol.com. |
| pumabiotechnology.com. | NS | 3600 | NS Record: ns68.domaincontrol.com. |
| pumabiotechnology.com. | MX | 1800 | MX Record: 10 pumabiotechnology.in.tmes.trendmicro.com. |
| pumabiotechnology.com. | TXT | 1800 | TXT Record: v=spf1 include:spf.protection.outlook.com include:spf.tmes.trendmicro.com ip4:38.71.0.160/28 ip4:64.235.144.0/20 ip4:209.222.80.0/21 ip4:135.84.68.123 ip4:208.86.168.7 include:spf_c.oraclecloud.com include:mailgun.org ip4:204.236.134.182/32 ip4:65.141.178 .112/28 ip4:174.129.192.189 ip4:174.129.8.146 ip4:207.178.204.18/28 ip4:147.154.97.253 ip4:199.91.136.26 ip4:205.201.128.0/20 ip4:198.2.128.0/18 ip4:148.105.8.0/21 ip4:66.179.217.30 ip4:66.35.231.15/32 ip4:66.35.231.16/32 ip4:66.35.231.17/32 ip4:66.35.231 .18/32 ip4:216.74.162.13/32 ip4:216.74.162.14/32 ip4:216.74.162.15/32 ip4:216.74.162.16/32 ip4:216.74.162.17/32 ip4:216.74.162.18/32 IP4:174.129.192.189 -all |
| pumabiotechnology.com. | TXT | 1800 | TXT Record: apple-domain-verification=vrD3C8fnODSfTjIw |
| pumabiotechnology.com. | TXT | 1800 | TXT Record: adobe-idp-site-verification=344f651bcde93f4d8514330737643712673cc5bc8c8e413e629c5697b42696f5 |
| pumabiotechnology.com. | TXT | 1800 | TXT Record: tmes=c018838f1b2432c3eb7c78d79ea69abd |
| pumabiotechnology.com. | TXT | 1800 | TXT Record: 84hjnbbhj0cr9cscu374sm59nj |
HtmlToTextCheckTime:2023-04-28 16:12:52
| In September 2022, Puma Biotechnology entered into an exclusive license agreement with Takeda for the development and commercialization of alisertib, an investigational aurora kinase A inhibitor. Read More Apr. 20, 2023 - Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results Read Mar. 14, 2023 - Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology Read Mar. 2, 2023 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results Read Feb. 28, 2023 - Puma Biotechnology to Participate in a Panel Discussion at Cowens 43rd Annual Health Care Conference Read Feb. 16, 2023 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results Read Feb. 1, 2023 - Puma Biotechnologys NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation Read Jan. 12, 2023 - Puma Biotechnology to Present at B. Riley Securities |
HTTP Headers
HTTP/1.1 302 Found Date: Thu, 21 Oct 2021 15:37:41 GMT Server: Apache Location: https://pumabiotechnology.com/ Content-Type: text/html; charset=iso-8859-1 HTTP/2 200 last-modified: Tue, 21 Sep 2021 20:16:09 GMT etag: "100443-9287-5cc87118022e1" accept-ranges: bytes content-length: 37511 vary: Accept-Encoding content-type: text/html date: Thu, 21 Oct 2021 15:37:41 GMT server: Apache |
pumabiotechnology.com Whois Information
Domain Name: PUMABIOTECHNOLOGY.COM Registry Domain ID: 1612945298_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2021-08-27T14:14:13Z Creation Date: 2010-08-26T19:52:17Z Registry Expiry Date: 2022-08-26T19:52:17Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS67.DOMAINCONTROL.COM Name Server: NS68.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2021-09-10T10:01:52Z <<< |